Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome
| Status: | Completed |
|---|---|
| Conditions: | Ocular |
| Therapuetic Areas: | Ophthalmology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 12/24/2017 |
| Start Date: | July 2010 |
| End Date: | June 15, 2015 |
The investigators hypothesize that oral omega-3-acid ethyl esters (Lovaza, GlaxoSmithKline,
Research Triangle Park, NC) will decrease dry-eye related symptoms as well as clinical
markers associated with dry eye disease (Schirmer-1 test values, positive vital staining with
lissamine green, and fluorescein tear break-up time) when compared to administration of
placebo.
Research Triangle Park, NC) will decrease dry-eye related symptoms as well as clinical
markers associated with dry eye disease (Schirmer-1 test values, positive vital staining with
lissamine green, and fluorescein tear break-up time) when compared to administration of
placebo.
Inclusion Criteria:
- Age > 18 years
- Typical symptoms of dry eye (photophobia, burning, foreign body sensation, blurred
vision improved with blinking)
- Schirmer Test < 8 mm/5 minutes
- Fluorescein tear break-up time < 8 seconds
- No current use of dry eye treatment (except artificial lubrication)
- Signature on consent form
Exclusion Criteria:
- Infectious keratoconjunctivitis or inflammatory disease unrelated to dry eye
- Eyelid or eyelash abnormalities
- Alteration of the nasolacrimal apparatus
- Treatment with drugs affecting tearing
- Concomitant ocular therapies
- Topical ophthalmic steroids taken during the 4 weeks before the study
- Pregnant/breast-feeding women
- History of liver disease
- History of fish and/or shellfish allergy or hypersensitivity
- History of corn allergy or hypersensitivity
- Treatment with systemic anticoagulation therapy
- Patients with bleeding disorders or those receiving anticoagulation (e.g., warfarin,
enoxaparin, dipyridamole, clopidogrel)
We found this trial at
1
site
Click here to add this to my saved trials
